<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="reply">
  <front>
    <journal-meta>
      <journal-id journal-id-type="hwp">jinfdis</journal-id>
      <journal-id journal-id-type="publisher-id">jid</journal-id>
      <journal-title>The Journal of Infectious Diseases</journal-title>
      <abbrev-journal-title>The Journal of Infectious Diseases</abbrev-journal-title>
      <issn pub-type="ppub">0022-1899</issn>
      <issn pub-type="epub">1537-6613</issn>
      <publisher>
        <publisher-name>The University of Chicago Press</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="doi">10.1086/315900</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Correspondence</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Reply</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Trollfors</surname>
            <given-names>B.</given-names>
          </name>
          <xref ref-type="aff" rid="AFF1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Schneerson</surname>
            <given-names>R.</given-names>
          </name>
          <xref ref-type="aff" rid="AFF2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Robbins</surname>
            <given-names>J. B.</given-names>
          </name>
          <xref ref-type="aff" rid="AFF2">
            <sup>2</sup>
          </xref>
          <xref rid="cor1" ref-type="corresp"/>
        </contrib>
        <aff id="AFF1"><sup>1</sup><institution>Gotebörg Pertussis Vaccine Study, Gotebörg Primary Health Care System</institution>, <addr-line>Gotebörg</addr-line>, <country>Sweden</country></aff>
        <aff id="AFF2"><sup>2</sup><institution>National Institute of Child Health and Human Development, National Institutes of Health</institution>, <addr-line>Bethesda, Maryland</addr-line></aff>
      </contrib-group>
      <author-notes>
        <corresp id="cor1">Reprints or correspondence: Dr. John B. Robbins, National Institute of Child Health and Human Development, Bldg. 6, Rm. 424, Bethesda, MD 20892 (<email>robbinsjo@nih.gov</email>).</corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <month>11</month>
        <year>2000</year>
      </pub-date>
      <volume>182</volume>
      <issue>5</issue>
      <fpage>1576</fpage>
      <lpage>1577</lpage>
      <copyright-statement>© 2000 by the Infectious Diseases Society of America</copyright-statement>
      <copyright-year>2000</copyright-year>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>To the Editor</title>
      <p>Our article [<xref ref-type="bibr" rid="R1">1</xref>] confirms reports that serum IgG anti—pertussis toxin (PT) alone confers immunity to infection with <italic>Bordetella pertussis</italic>. Although <xref ref-type="bibr" rid="R2">Cassone et al. [2]</xref> indicate that the mouse provides a “reliable” model, mice neither cough nor transmit <italic>B. pertussis</italic>. These 2 activities are essential components of pertussis. Furthermore, PT, either by active immunization or by passive immunization with polyclonal or monoclonal antibodies at levels that can be achieved clinically, is the only component of <italic>B. pertussis</italic> that confers 100% protection against both intracerebral and pulmonary challenge of mice [<xref ref-type="bibr" rid="R3">3</xref>].</p>
      <p>Two reports show that pertussis occurs in the absence of only PT antibodies in humans [<xref ref-type="bibr" rid="R4">4</xref>, <xref ref-type="bibr" rid="R5">5</xref>]. Further, convalescence from infection with <italic>Bordetella parapertussis</italic> induces high levels of antibodies to the filamentous hemagglutinin (FHA) and pertactin but does not confer immunity to pertussis [<xref ref-type="bibr" rid="R6">6</xref>, <xref ref-type="bibr" rid="R7">7</xref>]. It has also been reported that antibodies to FHA and pertactin do not confer immunity to pertussis [<xref ref-type="bibr" rid="R8">8</xref>, <xref ref-type="bibr" rid="R9">9</xref>]. The action of PT antibodies is not directly antibacterial and has been shown to be analogous to vaccine-induced antitoxin-mediated immunity to diphtheria [<xref ref-type="bibr" rid="R10">10</xref>]. Vaccination can only prevent disease, including pertussis, but cannot cure established infection [<xref ref-type="bibr" rid="R11">11</xref>].</p>
      <p>As for T cell—mediated immunity, the authors did not demonstrate a statistically significant relation between immunity to pertussis and the degree of peripheral blood mononuclear cell (PBMC) proliferation to PT or to their description of “sero-responder.” Their notion that immunity can exist in the absence of a protective level of anti-PT is not consistent with data observed after vaccination. Vaccine or disease-mediated immunity lasts one to several decades. Serum anti-PT declines with time to nondetectable levels parallel to increased susceptibility to pertussis. But, in older persons, immunologic memory to PT persists, as shown by the rapid antibody increase after vaccination. Curiously, the authors do not explain why their PBMC stimulation index increases with the interval after vaccination, when both the levels of anti-PT and resistance to pertussis decrease.</p>
      <p>The best explanation for the decline in resistance to pertussis after immunization is that a critical level of IgG anti-PT is essential for immunity to infection with <italic>B. pertussis</italic>, as has been shown for other respiratory bacterial pathogens, such as diphtheria, <italic>Haemophilus influenzae</italic> type b, meningococci, and pneumococci [<xref ref-type="bibr" rid="R11">11</xref>]. It is well known that other components of the host response participate in the inactivation and disposal of pathogens after their combination with antigens (e.g., PT, including complement activation, opsonization, and release of cytokines).</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <title>References</title>
      <ref id="R1">
        <label>1.</label>
        <nlm-citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Taranger</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Trollfors</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Lagergard</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Correlation between pertussis toxin IgG antibodies in postvaccination sera and subsequent protection against pertussis</article-title>
          <source>J Infect Dis</source>
          <year>2000</year>
          <volume>181</volume>
          <fpage>1010</fpage>
          <lpage>3</lpage>
        </nlm-citation>
      </ref>
      <ref id="R2">
        <label>2.</label>
        <nlm-citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cassone</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Mastrantonio</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Ausiello</surname>
              <given-names>CM</given-names>
            </name>
          </person-group>
          <article-title>Are only antibody levels involved in the protection against pertussis in acellular pertussis vaccine recipients? [letter]</article-title>
          <source>J Infect Dis</source>
          <year>2000</year>
          <volume>182</volume>
          <fpage>1575</fpage>
          <lpage>6</lpage>
          <comment>(in this issue)</comment>
        </nlm-citation>
      </ref>
      <ref id="R3">
        <label>3.</label>
        <nlm-citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Robbins</surname>
              <given-names>JB</given-names>
            </name>
            <name>
              <surname>Pittman</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Trollfors</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Lagergard</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Taranger</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Schneerson</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Primum non nocere: a pharmacologically inert pertussis toxoid alone should be the next pertussis vaccine</article-title>
          <source>Pediatr Infect Dis J</source>
          <year>1993</year>
          <volume>12</volume>
          <fpage>795</fpage>
          <lpage>807</lpage>
        </nlm-citation>
      </ref>
      <ref id="R4">
        <label>4.</label>
        <nlm-citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zackrisson</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Taranger</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Trollfors</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>History of whooping cough in non-vaccinated Swedish children, related to serum antibodies to pertussis toxin and filamentous hemagglutinin</article-title>
          <source>J Pediatr</source>
          <year>1990</year>
          <volume>116</volume>
          <fpage>190</fpage>
          <lpage>4</lpage>
        </nlm-citation>
      </ref>
      <ref id="R5">
        <label>5.</label>
        <nlm-citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Granström</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Granström</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Serological correlates in whooping cough</article-title>
          <source>Vaccine</source>
          <year>1993</year>
          <volume>11</volume>
          <fpage>445</fpage>
          <lpage>8</lpage>
        </nlm-citation>
      </ref>
      <ref id="R6">
        <label>6.</label>
        <nlm-citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Taranger</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Trollfors</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Lagergard</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Zackrisson</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Parapertussis infection followed by pertussis infection</article-title>
          <source>Lancet</source>
          <year>1994</year>
          <volume>344</volume>
          <fpage>1703</fpage>
        </nlm-citation>
      </ref>
      <ref id="R7">
        <label>7.</label>
        <nlm-citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Liese</surname>
              <given-names>JG</given-names>
            </name>
            <name>
              <surname>Meschievitz</surname>
              <given-names>CK</given-names>
            </name>
            <name>
              <surname>Harzer</surname>
              <given-names>E</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Efficacy of a two-component acellular pertussis vaccine in infants</article-title>
          <source>Pediatr Infect Dis J</source>
          <year>1997</year>
          <volume>16</volume>
          <fpage>1038</fpage>
          <lpage>44</lpage>
        </nlm-citation>
      </ref>
      <ref id="R8">
        <label>8.</label>
        <nlm-citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bergfors</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Trollfors</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Taranger</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Lagergard</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Sundh</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Zackrisson</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Parapertussis and pertussis: differences and similarities in incidence, clinical course, and antibody response</article-title>
          <source>Int J Infect Dis</source>
          <year>1999</year>
          <volume>3</volume>
          <fpage>140</fpage>
          <lpage>6</lpage>
        </nlm-citation>
      </ref>
      <ref id="R9">
        <label>9.</label>
        <nlm-citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cherry</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Olin</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>The science and fiction of pertussis vaccines</article-title>
          <source>Pediatrics</source>
          <year>1999</year>
          <volume>104</volume>
          <fpage>1381</fpage>
          <lpage>3</lpage>
        </nlm-citation>
      </ref>
      <ref id="R10">
        <label>10.</label>
        <nlm-citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schneerson</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Robbins</surname>
              <given-names>JB</given-names>
            </name>
            <name>
              <surname>Taranger</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Lagergard</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Trollfors</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>A toxoid vaccine for pertussis as well as diphtheria? Lessons to be relearned</article-title>
          <source>Lancet</source>
          <year>1996</year>
          <volume>348</volume>
          <fpage>1289</fpage>
          <lpage>92</lpage>
        </nlm-citation>
      </ref>
      <ref id="R11">
        <label>11.</label>
        <nlm-citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Robbins</surname>
              <given-names>JB</given-names>
            </name>
            <name>
              <surname>Schneerson</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Szu</surname>
              <given-names>SC</given-names>
            </name>
          </person-group>
          <article-title>Perspective. Hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum</article-title>
          <source>J Infect Dis</source>
          <year>1995</year>
          <volume>171</volume>
          <fpage>1387</fpage>
          <lpage>98</lpage>
        </nlm-citation>
      </ref>
    </ref-list>
  </back>
</article>
